electroCore to Participate at Canaccord Genuity 42nd Annual Growth Conference
electroCore to Participate at Canaccord Genuity 42nd Annual Growth Conference
ROCKAWAY, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore's Chief Executive Officer, Dan Goldberger, will be presenting at the Canaccord Genuity 42nd Annual Growth Conference.
Canaccord Genuity 42nd Annual Growth Conference
Date: Thursday, August 11, 2022
Time: 8:30 AM EDT
Webcast: Canaccord Webcast
新澤西州羅克韋，2022年8月5日(環球網)--商用生物電子醫藥公司電芯公司(納斯達克代碼：ECOR)今天宣佈，電芯公司首席執行官丹·戈德伯格將出席Canaccel Genuity第42屆年度增長大會。
Canaccel Genuity第42屆年度增長大會
日期：2022年8月11日(星期四)
時間：美國東部夏令時上午8：30
網絡直播：Canaccel網絡直播
Following the conferences, a webcast replay of the presentations will be available on the Investor section of the company's website, electroCore.
會議結束後，演示文稿的網絡直播重播將在該公司網站的投資者欄目上播出，網址為ElectrCore。
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.
For more information, visit .
Investors:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital
關於電子核心公司
Electrcore，Inc.是一家商業階段的生物電子藥物公司，致力於通過其非侵入性迷走神經刺激治療平臺改善患者的預後，最初專注於神經科多種疾病的治療。該公司目前的適應症是叢集性頭痛和偏頭痛的預防性治療，偏頭痛和發作性叢集性頭痛的急性治療，青少年偏頭痛的急性和預防性治療，以及成人的陣發性偏頭痛和持續性偏頭痛。
有關更多信息，請訪問。
投資者：
裏奇·科克雷爾
CG資本
404-736-3838
郵箱：ecor@cg.Capital